BioXcel Therapeutics granted Nasdaq listing extension to Sept 16, 2025

BioXcel Therapeutics, Inc.

Nasdaq Hearings Panel extended compliance deadline for MVLS Rule (minimum $35M market value for 10 consecutive days) to September 16, 2025.
Extension is subject to BioXcel meeting certain interim conditions set by the Panel.
Company previously faced potential delisting for failing to satisfy Nasdaq Listing Rule 5550(b)(2).
Decision follows review of BioXcel's compliance plan and strategies for long-term compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.